Does targeted therapy treat multiple myeloma?

Multiple myeloma is a blood cancer involving abnormal plasma cells in the bone marrow. Targeted medicines interfere with proteins or processes that myeloma cells rely on. They are often combined with other medicines, and the plan can change between newly diagnosed disease, treatment response, and relapse. Kidney function, blood counts, infections, bone problems, and other health conditions affect safe selection and dosing.

Ask the haematology team why a particular combination was selected and whether treatment is intended to reduce disease, maintain control, or prepare for another step. Keep a current medicine list and tell the team about numbness, previous infections, kidney concerns, and vaccinations. Follow the requested blood and urine checks; these help track blood counts, kidney function, protein levels, and treatment effects.

Call the care team urgently for fever, chills, unusual bruising, bleeding, worsening weakness, or signs of infection. Seek emergency help for severe back pain with leg weakness, loss of bladder or bowel control, sudden confusion, or difficulty breathing. Myeloma can affect bones, blood cells, kidneys, and immunity, so these changes should not wait for a routine visit.

What is the aim of this targeted medicine? How does it fit with the other medicines in my plan? What monitoring is needed for blood counts and kidney function? What should I do if I develop a fever or new numbness?